DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Hosted on MSN
Over the past decade, early-stage drug innovation has shifted toward China, researchers find
In 2015, about 48% of early-stage programs originated in the U.S. and 8% in China. By 2024, the U.S. share had declined to just over 37%, while China's share rose to just over 32%. Overall, the number ...
SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for ...
Novartis’ RNA production facility in Schweizerhalle, Switzerland. Novartis is acquiring Avidity Biosciences for approximately $12 billion, in a deal designed to bolster the buyer’s neuroscience ...
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the financing are expected to fund operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results